TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01475513

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ortho Cyclen®
Description: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) will be taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ortho Cyclen®
Description: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) will be taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.
Study: NCT00158301

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: CBT sessions will focus on teaching participants skills to manage depressed moods and to identify situations which might put them at risk for a relapse in depressive symptoms.
Study: NCT01797289

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lung CT or V/Q scanning in patients with a high pre-test clinical probability of PE and/or a positive D-dimer
Study: NCT04130230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine
Description: Neostigmine continuous infusion plus standard therapy for sepsis and septic shock.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard therapy
Description: Standard therapy for sepsis and septic shock
Study: NCT02515045

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TriMoxiVanc
Description: triamcinolone acetonide 15 mg / ml with moxifloxacin 1 mg/ml, vancomycin 10 mg/ml to be injected at time of cataract surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TriMoxiVanc
Description: triamcinolone acetonide 15 mg / ml with moxifloxacin 1 mg/ml, vancomycin 10 mg/ml to be injected at time of cataract surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin HCl 0.5%
Description: Antibiotic to be used 1 drop, QID for 3 days prior to surgery and will continue for 2 weeks after surgery and then discontinue.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ilevro
Description: NSAID to be used 1 drop QD starting 3 days before surgery and QD for 4 weeks after surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ilevro
Description: NSAID to be used 1 drop QD starting 3 days before surgery and QD for 4 weeks after surgery.
Study: NCT01331850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: 1000 mg or 1200 mg daily oral doses for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: 180 microgram subcutaneously once weekly for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: 180 microgram subcutaneously once weekly for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: 180 microgram subcutaneously once weekly for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: 180 microgram subcutaneously once weekly for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048
Description: 1000 mg oral doses twice a day for 24 weeks
Study: NCT02515045

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone acetate 1%
Description: Steroid to be started after surgery 1 drop QID for 2 weeks, tapered to BID for 2 weeks, and then discontinued.
Study: NCT04400838

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 (Abs 260)
Description: A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 measured by spectrophotometry at Abs260

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 (Abs 260)
Description: A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 measured by spectrophotometry at Abs260

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 (Abs 260)
Description: A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 measured by spectrophotometry at Abs260

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 (Abs 260)
Description: A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 measured by spectrophotometry at Abs260
Study: NCT01331850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048
Description: 1000 mg oral doses twice a day for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048
Description: 1000 mg oral doses twice a day for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048
Description: 1000 mg oral doses twice a day for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048
Description: 1000 mg oral doses twice a day for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: 100 mg oral doses twice a day for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: 100 mg oral doses twice a day for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: 100 mg oral doses twice a day for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: 100 mg oral doses twice a day for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: 100 mg oral doses twice a day for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: 100 mg oral doses twice a day for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: 100 mg oral doses twice a day for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: 100 mg oral doses twice a day for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: 100 mg oral doses twice a day for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: 100 mg oral doses twice a day for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: 100 mg oral doses twice a day for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: 100 mg oral doses twice a day for 24 weeks
Study: NCT04190758

Intervention type: OTHER
Intervention: Care as usual
Description: No intervention will be given. The study will follow the effects of care as usual.

Intervention type: OTHER
Intervention: Care as usual
Description: No intervention will be given. The study will follow the effects of care as usual.

Intervention type: OTHER
Intervention: Care as usual
Description: No intervention will be given. The study will follow the effects of care as usual.

Intervention type: OTHER
Intervention: Care as usual
Description: No intervention will be given. The study will follow the effects of care as usual.
Study: NCT04366323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS
Description: Two doses of 80 million adipose-tissue derived mesenchymal stem cells
Study: NCT00402116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: Phase 1 - 250 mg Cohort 1 with one dose escalation allowed to 500 mg for Cohort 2, oral, daily, 6 weeks then twelve 28 day cycles~Phase 2 - Phase 1 established dose, oral, daily, 6 weeks then twelve 28 day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: 75 milligrams per meter squared (mg/m\^2), oral, daily, 6 weeks then 200 mg/m\^2, oral, daily, twelve 28 day cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 1.8-2.0 Gy x 30 fractions, 5 days/week, for 6 weeks
Study: NCT00577603

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mesh reinforcement of stoma
Description: Patients randomized to receive mesh will undergo stoma formation and will have a 8 cm x 12 cm piece of AlloDerm graft placed as a tissue reinforcement around the stoma and extending under the midline incision. The mesh will be trimmed to provide a minimum of 3cm of overlap around the stoma in all directions. The mesh will be secured with transabdominal number one Prolene (Ethicon, Inc) sutures every 4cm around the mesh. Additional fixation will be provided with Protack spiral tacks (US Surgical, Inc) every 1cm around the mesh. The midline fascia will be closed with running number one Prolene sutures. Skin will be closed in standard fashion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no intervention
Study: NCT00158301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug therapy
Description: All participants will receive 12 weeks of treatment with antidepressant therapy. Responders to initial treatment will continue medication during the continuation phase (both treatment arms).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug therapy
Description: All participants will receive 12 weeks of treatment with antidepressant therapy. Responders to initial treatment will continue medication during the continuation phase (both treatment arms).
Study: NCT00001151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1,25-Dihydroxycholecalciferol
Description: Usual doses of 1,25-dihydroycholecalciferol are 0.25-1 ug per day. All patients in this study received very high doses or 5-20 ug per day.
Study: NCT01047215

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole; Quetiapine
Description: Aripiprazole Quetiapine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole; Quetiapine
Description: Aripiprazole Quetiapine
Study: NCT00983151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Hydrochloride & Placebo
Description: 89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours) Subject will take the study drug for about 27 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tramadol Hydrochloride & Placebo
Description: 89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours) Subject will take the study drug for about 27 weeks
Study: NCT01429272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline
Description: 100 mg po bid for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 81 mg po bid for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo for minocycline and/or aspirin
Study: NCT03418909

Intervention type: PROCEDURE
Intervention: Primary Trans Oral Robotic Surgery (TORS)
Description: In the absence of severe mobidity patients with early stage disease (T1-2, N1, M0) were offered TORS, as an alternative to the standard of care (radiotherapy).

Intervention type: RADIATION
Intervention: Radio(chemo)therapy
Description: As the standard of care radiotherapy was offered to all of the patients. Patients that qualified for both TORS and radiotherapy were free to choose between the two.
Study: NCT04116138

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salovum
Description: Egg yolk powder enriched for anti secretory factor
Study: NCT01062555

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine & Cellcept
Description: Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf & Cellcept
Description: Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose CNI (Cyclosporine or FK) and Cellcept
Description: Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapamune and Cellcept
Description: Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
Study: NCT03035955

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azelaic acid
Description: 15% gel twice daily for four weeks to one side of face
Study: NCT01470742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: D1-14 Capecitabine 1000mg/m2 bid D1 Oxaliplatin 110mg/m2 + D5W 250ml over 2hr every 3weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELODA
Description: Capecitabine 1000mg/m2 bid D1-14 every 3weeks
Study: NCT02488603

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision aids (tamoxifen-related educational materials in brochure or mobile app)
Description: Decision aids (tamoxifen-related educational materials in brochure or mobile app)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen
Study: NCT03836196

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: LDR Brachytherapy and External Beam Radiation Therapy
Description: Low Dose Rate Brachytherapy (LDR-PB) and External Beam Radiation Therapy (EBRT)
Study: NCT00978068

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/Ritonavir (LPV/r)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine (NVP)
Description: NVP will be used for children \< 3 years of age

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz (EFV)
Description: EFV for children ≥3 years of age

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 nucleoside reverse transcriptase inhibitor (NRTI)
Description: The same NRTI choice strategy will be used for both arms. Lamivudine will be used with all children. The second NRTI will be zidovudine unless the participant has a hemoglobin \< 8 gm/dL, in which case it will be Abacavir. Stavudine will be used in the event that a participant is unable to take Abacavir for safety or other reasons.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 nucleoside reverse transcriptase inhibitor (NRTI)
Description: The same NRTI choice strategy will be used for both arms. Lamivudine will be used with all children. The second NRTI will be zidovudine unless the participant has a hemoglobin \< 8 gm/dL, in which case it will be Abacavir. Stavudine will be used in the event that a participant is unable to take Abacavir for safety or other reasons.
Study: NCT03486093

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Training and retraining to GAVECELT bundle recommendations plus port protector
Description: Physicians and nurses of RICU have been trained and retrained to GAVECELT bundle recommendations concerning the management of CVC. The bundle includes: hand hygiene and precautions for protection and safety, adequate insertion site, echo-guided placement of central venous line, use of clorexidine 2% for skin disinfection of insertion site chosen and subsequent continuous or discontinuous disinfection of exit site, use of suture-less devices, use of transparent semi-permeable dressing whenever applicable and immediate removal of catheter when no longer needed.~After the first training meeting, the use of Curos® Disinfecting Port Protector for needleless valves port-protector has been introduced.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training and retraining to GAVECELT bundle recommendations
Description: Physicians and nurses of RICU have been trained and retrained to GAVECELT bundle recommendations concerning the management of CVC. The bundle includes: hand hygiene and precautions for protection and safety, adequate insertion site, echo-guided placement of central venous line, use of clorexidine 2% for skin disinfection of insertion site chosen and subsequent continuous or discontinuous disinfection of exit site, use of suture-less devices, use of transparent semi-permeable dressing whenever applicable and immediate removal of catheter when no longer needed.
Study: NCT03010111

Intervention type: OTHER
Group type: OTHER
Intervention: QFT-IT Test and other blood sampling
Description: In all enrolled health care workers, QFT-IT Test and other blood sampling were performed.
Study: NCT03526458

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Holmium:YAG laser
Description: Treatment of urolithiasis is commonly done using the holmium:YAG laser as this has been shown to be a safe and effective method of treating a wide variety of stones and is currently considered the standard of care (AUA Guideline Panel on the Surgical Management of Stones)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holmium:YAG laser
Description: Treatment of urolithiasis is commonly done using the holmium:YAG laser as this has been shown to be a safe and effective method of treating a wide variety of stones and is currently considered the standard of care (AUA Guideline Panel on the Surgical Management of Stones)
Study: NCT04910009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Four sessions of practical privacy education
Description: Two sessions of theoretical, four sessions of practical privacy education

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Four sessions of practical privacy education
Description: Two sessions of theoretical, four sessions of practical privacy education
Study: NCT01867463

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs25-EPA/Alhydrogel
Description: The Pfs25-EPA conjugate was produced by reaction between thiolated PpPfs25 and maleimideactivated EcEPA, followed by purification using size-exclusion chromatography. The cGMP Pfs25-EPA conjugate Lot# WRAIR1634 was manufactured at Walter Reed Bioproduction facility in cGMP compliance in May 2010. Alhydrogel (Brenntag, Denmark) is an aluminum hydroxide gel and has been extensively used as an adjuvant in licensed human vaccines. Alhydrogel is supplied as a sterile product in water without preservatives. Pfs25- EPA/Alhydrogel WRAIR Lot #1668 was manufactured and filled as single-use vials at Walter Reed Bioproduction facility in cGMP compliance in October 2010. Each vial contains 78 g/mL conjugated Pfs25, 93 g/mL conjugated EPA and 1600 g/mL Alhydrogel in a volume of 0.8 mL. The vial label reads: 78 g/mL Conjugated Pfs25 on Alhydrogel .
Study: NCT02918149

Intervention type: OTHER
Group type: OTHER
Intervention: Palpation Landmark Technique
Description: Clinician will follow routine palpation landmark technique procedure for LP, such as identification of anatomic landmarks by palpation (i.e., superior borders of the posterior iliac crest lies in parallel with L4 spinous process). Palpation will be followed by blind stick of the appropriate inter-spinous process space. The study member will have 2 attempts to complete the LP. A successful attempt is obtaining cerebrospinal fluid.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound-Assisted Technique LP
Description: Clinician will use an ultrasound-assisted technique to perform the LP. The Phillips CX50 ultrasound machine is an FDA approved device and will be used in accordance with its approved labeling. Spinal ultrasound will be performed using a linear high-frequency transducer to locate and mark the termination of the conus medullaris, the narrowing of the spinal canal, and the midline to delineate a safe zone. The study team member will have 2 attempts to complete the LP. A successful attempt is obtaining cerebrospinal fluid.
Study: NCT00586183

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET scan
Description: The subject will then be positioned in the PET scanner . After optimal positioning of the left ventricle within the field of view, a transmission scan will be performed with either a germanium-68 or CT source for subsequent attenuation correction.
Study: NCT03187457

Intervention type: OTHER
Group type: OTHER
Intervention: Metronidazole
Description: Women with Bacterial Vaginosis treated with Metronidazole for 5 days

Intervention type: OTHER
Group type: OTHER
Intervention: Control: no treatment
Description: Healthy women without Bacterial Vaginosis
Study: NCT03293732

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCB07010
Description: A protein based adjuvant originated from prokaryotic organism.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCB07010
Description: A protein based adjuvant originated from prokaryotic organism.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCB07010
Description: A protein based adjuvant originated from prokaryotic organism.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCB07010
Description: A protein based adjuvant originated from prokaryotic organism.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HA antigens
Description: HA antigens from three strains of influenza virus ( 7.5 μg of HA each strain).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HA antigens
Description: HA antigens from three strains of influenza virus ( 7.5 μg of HA each strain).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HA antigens
Description: HA antigens from three strains of influenza virus ( 7.5 μg of HA each strain).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HA antigens
Description: HA antigens from three strains of influenza virus ( 7.5 μg of HA each strain).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HA antigens
Description: HA antigens from three strains of influenza virus ( 7.5 μg of HA each strain).
Study: NCT02912234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Multiple-dose clarithromycin and single-dose Apixaban

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Multiple-dose clarithromycin and single-dose Apixaban
Study: NCT00827255

Intervention type: DRUG
Intervention: Cyclosporine Ophthalmic Emulsion 0.05%
Description: One drop two times a day approximately 12 hours apart
Study: NCT00644293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin (Zithromax)
Description: azithromycin 500 mg tablet by mouth once daily for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin SR
Description: azithromycin SR 2.0 g by mouth as an oral slurry for 1 dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo
Study: NCT04404855

Intervention type: OTHER
Group type: OTHER
Intervention: NGS + Antibiotic Recommendation
Description: NGS results in addition to recommended antibiotic therapy made by infectious disease pharmacist

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard of Care treatment
Description: Subjects will have a standard of care urine culture and prophylactic antibiotic prescribed per routine care.